UBX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-04-28 | 2021 | Jamie Dananberg, M.D., Chief Medical Officer | 455,281 | 0 | 104,500 | 168,909 | 11,600 | 1,042,860 |
| 2023-04-28 | 2022 | Jamie Dananberg, M.D., Chief Medical Officer | 464,386 | 100,000 | 48,583 | 167,719 | 12,200 | 743,765 |
| 2023-04-28 | 2021 | Lynne Sullivan, Chief Financial Officer and Head of Corporate Development | 440,000 | 0 | 128,882 | 163,240 | 11,600 | 1,116,891 |
| 2023-04-28 | 2022 | Lynne Sullivan, Chief Financial Officer and Head of Corporate Development | 453,200 | 100,000 | 53,000 | 165,418 | 12,200 | 730,818 |
| 2023-04-28 | 2021 | Anirvan Ghosh, Ph.D., Chief Executive Officer | 562,376 | 0 | 1,515,519 | 284,562 | 38,600 | 3,936,710 |
| 2023-04-28 | 2022 | Anirvan Ghosh, Ph.D., Chief Executive Officer | 580,000 | 200,000 | 150,167 | 287,100 | 12,200 | 1,085,300 |
| 2022-04-29 | 2021 | Anirvan Ghosh, Ph.D., Chief Executive Officer | 562,376 | 0 | 1,515,519 | 284,562 | 38,600 | 3,936,710 |
| 2022-04-29 | 2020 | Anirvan Ghosh, Ph.D., Chief Executive Officer | 416,737 | 75,000 | 2,482,500 | 213,263 | 53,571 | 7,399,096 |
| 2022-04-29 | 2021 | Lynne Sullivan, Chief Financial Officer and Head of Corporate Development | 440,000 | 0 | 128,882 | 163,240 | 11,600 | 1,116,891 |
| 2022-04-29 | 2020 | Lynne Sullivan, Chief Financial Officer and Head of Corporate Development | 166,667 | 0 | 705,600 | 66,696 | 4,667 | 2,856,022 |
| 2022-04-29 | 2021 | Jamie Dananberg, M.D., Chief Medical Officer | 455,281 | 0 | 104,500 | 168,909 | 11,600 | 1,042,860 |
| 2022-04-29 | 2020 | Jamie Dananberg, M.D., Chief Medical Officer | 442,020 | 0 | 849,917 | 172,167 | 11,400 | 1,913,558 |
| 2021-04-30 | 2019 | Jamie Dananberg, M.D., Chief Medical Officer | 428,500 | 0 | 189,675 | 182,005 | 11,200 | 1,591,853 |
| 2021-04-30 | 2020 | Anirvan Ghosh, Ph.D., Chief Executive Officer | 416,737 | 75,000 | 2,482,500 | 213,263 | 53,571 | 7,399,096 |
| 2021-04-30 | 2020 | Keith R. Leonard Jr., Chairman and former Chief Executive Officer | 201,541 | 0 | 0 | 0 | 40,644 | 576,355 |
| 2021-04-30 | 2019 | Keith R. Leonard Jr., Chairman and former Chief Executive Officer | 550,000 | 0 | 360,000 | 306,281 | 154,513 | 3,270,822 |
| 2021-04-30 | 2020 | Lynne Sullivan, Chief Financial Officer and Head of Corporate Development | 166,667 | 0 | 705,600 | 66,696 | 4,667 | 2,856,022 |
| 2021-04-30 | 2020 | Jamie Dananberg, M.D., Chief Medical Officer | 442,020 | 0 | 849,917 | 172,167 | 11,400 | 1,913,558 |
| 2020-04-24 | 2019 | Keith R. Leonard, Jr. Chairman and former Chief Executive Officer | 550,000 | 0 | 360,000 | 306,281 | 154,513 | 3,270,822 |
| 2020-04-24 | 2018 | Keith R. Leonard, Jr. Chairman and former Chief Executive Officer | 500,000 | 0 | 0 | 262,500 | 133,524 | 2,725,275 |
| 2020-04-24 | 2019 | Nathaniel E. David, Ph.D. President | 450,000 | 0 | 189,675 | 179,663 | 11,200 | 1,611,011 |
| 2020-04-24 | 2018 | Nathaniel E. David, Ph.D. President | 437,750 | 0 | 0 | 175,932 | 1,639,038 | 2,863,991 |
| 2020-04-24 | 2019 | Robert C. Goeltz II Chief Financial Officer | 400,000 | 0 | 189,675 | 166,100 | 11,200 | 1,620,891 |
| 2020-04-24 | 2018 | Robert C. Goeltz II Chief Financial Officer | 373,068 | 0 | 0 | 142,325 | 0 | 908,046 |
| 2019-04-26 | 2018 | Jamie Dananberg, M.D. Chief Medical Officer | 412,000 | 0 | 0 | 147,192 | 0 | 951,845 |
| 2019-04-26 | 2017 | Nathaniel E. David, Ph.D. President | 425,000 | 0 | 0 | 169,575 | 0 | 2,568,254 |
| 2019-04-26 | 2018 | Nathaniel E. David, Ph.D. President | 437,750 | 0 | 0 | 175,932 | 1,639,038 | 2,863,991 |
| 2019-04-26 | 2017 | Keith R. Leonard Jr. Chief Executive Officer | 485,000 | 0 | 0 | 237,650 | 115,521 | 4,026,896 |
| 2019-04-26 | 2018 | Keith R. Leonard Jr. Chief Executive Officer | 500,000 | 0 | 0 | 262,500 | 133,524 | 2,725,275 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
